Indapta Therapeutics key facts
as of Oct 2026- Operator of a biotechnology company focused on developing a natural killer cell therapy with potent activity to treat cancer.
- Indapta Therapeutics is valued at approximately $90.0M as of Oct 2026 (last reported valuation).
- It has raised $162.3M across 4 recorded rounds; the latest was Later Stage VC ($50.8M) in Sep 2025.
- Notable investors include RA Capital Management, Cancer Prevention and Research Institute of Texas, Leaps by Bayer, Leerink Partners, Lonza Group — 11 tracked in total.
- Indapta Therapeutics has filed 1 Form D with the SEC, most recently Feb 2022 ($33.6M sold to 37 investors).
- Status: Privately Held (backing).
Indapta Therapeutics's last reported valuation, May 2023. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Indapta Therapeutics: the Monday email on marks, rounds and moves
Indapta Therapeutics funding rounds
4 roundsWho backs Indapta Therapeutics
11+Indapta Therapeutics valuation
Indapta Therapeutics's last reported valuation was $90 million in May 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Indapta Therapeutics raised?
Indapta Therapeutics has raised $162 million across 4 recorded rounds since 2022. The largest was an $80 million Series A in May 2023; the most recent was a $50.8 million later-stage round in Sep 2025.
Indapta Therapeutics has filed 1 Form D with the SEC, most recently in Feb 2022 ($33.6 million sold to 37 investors).
Indapta Therapeutics investors
11 investors are on record for Indapta Therapeutics, including RA Capital Management, Cancer Prevention and Research Institute of Texas, Leaps by Bayer and Leerink Partners. The later-stage round in Sep 2025 drew 46 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Sydnexis ($90 million), Hyku Biosciences ($85 million) and Linnaeus Therapeutics ($83.1 million).
About Indapta Therapeutics
Operator of a biotechnology company focused on developing a natural killer cell therapy with potent activity to treat cancer. The company specializes in commercializing a proprietary off-the-shelf, non-engineered, and allogeneic cell to boost the immune response and substantially improve the cytotoxicity of antibody therapy, enabling healthcare providers to treat patients suffering from cancer.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2017
- Employees
- 14
- Website
- indapta.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.